This material is intended for UK healthcare professionals only and intended to be viewed online. Prescribing Information can be found by clicking this link. Adverse event reporting information can be found at the bottom of this page.

A guide to using Beyfortus® (nirsevimab)

Beyfortus® is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:[1]

i. Neonates and infants during their first RSV season.
ii. Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Beyfortus® should be used in accordance with official recommendations.[1]

How to use Beyfortus®

First RSV season:

For neonates and infants based on **body weight at the time of dosing**[1]

Weight <5 kg
1 x 50 mg dose

Weight ≥5 kg
1 x 100 mg dose

Second RSV season:

For children who remain **vulnerable to severe RSV disease**, up to 24 months of age[1]

Regardless of body weight
200 mg administered as 2 x 100 mg in a single appointment

Beyfortus® is for intramuscular injection only, preferably in the anterolateral aspect of the thigh.[1] The gluteal muscle should not be used routinely as an injection site because of the risk of damage to the sciatic nerve.[1]

Consult the Summary of Product Characteristics prior to prescribing for full dosing and administration information.

Timing of administration[1]

For infants during their first RSV season[1]: Beyfortus® should be administered from birth for infants born during the RSV season. For others born outside the season, Beyfortus® should be administered ideally prior to the RSV season.

For children vulnerable to severe RSV disease through their second season:[1] Beyfortus® should be administered ideally prior to the start of the second RSV season.

How to store Beyfortus®[1]

Storage

- Store in a refrigerator (2°C–8°C)
- Do not freeze
- Do not shake or expose to direct heat
- Keep the pre-filled syringe in the outer carton in order to protect from light

Shelf life

- Beyfortus® has a shelf life of 4 years
- Beyfortus® may be kept at room temperature (20°C–25°C) when protected from light for a maximum of 48 hours. After this time, the syringe must be discarded

Click on the link to Sanofi's promotional website to learn more about Beyfortus®
https://pro.campus.sanofi/uk/products/beyfortus-nirsevimab

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Sanofi drug safety department on Tel: 0800 0902 314. Alternatively, send via email to UK-drugsafety@sanofi.com.

sanofi

This item has been produced by Sanofi. Sanofi & AstraZeneca are collaborating on the development and commercialisation of Beyfortus®. References: 1. Beyfortus® UK Summary of Product Characteristics (SmPC). MAT-XU-2501733 (v2.0) July 2026